WO2003046140A2 - Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample - Google Patents

Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample Download PDF

Info

Publication number
WO2003046140A2
WO2003046140A2 PCT/US2002/037861 US0237861W WO03046140A2 WO 2003046140 A2 WO2003046140 A2 WO 2003046140A2 US 0237861 W US0237861 W US 0237861W WO 03046140 A2 WO03046140 A2 WO 03046140A2
Authority
WO
WIPO (PCT)
Prior art keywords
detection
sample
troponin
antigens
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/037861
Other languages
English (en)
French (fr)
Other versions
WO2003046140A3 (en
Inventor
Franz Nolls
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diagenics International Corp
Original Assignee
Diagenics International Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagenics International Corp filed Critical Diagenics International Corp
Priority to EP02784596A priority Critical patent/EP1461616A4/en
Priority to CA002507024A priority patent/CA2507024A1/en
Priority to JP2003547575A priority patent/JP2005510696A/ja
Priority to AU2002346529A priority patent/AU2002346529B2/en
Publication of WO2003046140A2 publication Critical patent/WO2003046140A2/en
Publication of WO2003046140A3 publication Critical patent/WO2003046140A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Definitions

  • the present invention comprises an immunochemical assay for the detection of markers and the levels of the markers at different times following injury.
  • the present invention further comprises an immunochemical assay for simultaneous determination of at least two antigens in a sample comprising contacting the sample with a carrier molecule comprising at least two capture agents which specifically bind to the binding moiety of at least one antigen.
  • the immunochemical assay further comprises detection agents which bind to the antigens bound to the capture agents.
  • the detection agents may additionally be coupled to a detection probe or the detection agents may be added separately to the sample.
  • the carrier molecule also comprises a detection agent coupled to a detection probe and the detection agent specifically binds the antigens.
  • the assay of the present invention can be used to detect heart specific markers glycogenphosphorylase BB (GPBB) and cardiac troponin-1.
  • specific binding includes antibodies that bind to one antigen with higher affinity than other related antigens.
  • the antibody binds with an affinity of at least about lxlO 7 M, and binds to the predetermined antigen with an affinity that is at least twice greater than its affinity for binding to a non-specific antigen (i.e., BSA, casein) other than the predetermined antigen or a closely-related antigen.
  • a non-specific antigen i.e., BSA, casein
  • an antibody with specific binding affinity for troponin-I may bind troponin-I with higher affinity than troporiin-T.
  • an antibody recognizing an antigen and "an antibody specific for an antigen” are used interchangeably herein with the term “an antibody which binds specifically to an antigen.”
  • a total of 87 ⁇ l of the SMCC solution is added to the AP and allowed to stir for one hour at ambient temperature.
  • the modified AP solution is then dialyzed overnight against 2 liters of 30 mM triethanolamine pH 7.2 containing 5 mM magnesium chloride and 1 mM zinc chloride at 4°C.
  • a total of 1.35 mg of the SATA modified troponin-I is mixed with 4 mg of SMCC modified AP and allowed to stir for 24 hours at 4°C.
  • Mercaptoethylamine and iodoacetamide are added to the solution to a final concentration of 10 mM and allowed to stir for 20 minutes at ambient temperature.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2002/037861 2001-11-27 2002-11-26 Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample Ceased WO2003046140A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02784596A EP1461616A4 (en) 2001-11-27 2002-11-26 IMMUNOLOGICAL ASSAY AND KIT FOR EARLY AND SIMULTANEOUS DETECTION OF BIOCHEMICAL MARKERS IN THE SAMPLE OF A PATIENT
CA002507024A CA2507024A1 (en) 2001-11-27 2002-11-26 Immunoassay and kit for an early and simultaneous detection of biochemical markers in a patient's sample
JP2003547575A JP2005510696A (ja) 2001-11-27 2002-11-26 患者サンプル中の生化学的標識の迅速同時検出のための免疫分析法および免疫分析キット
AU2002346529A AU2002346529B2 (en) 2001-11-27 2002-11-26 Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33313301P 2001-11-27 2001-11-27
US60/333,133 2001-11-27

Publications (2)

Publication Number Publication Date
WO2003046140A2 true WO2003046140A2 (en) 2003-06-05
WO2003046140A3 WO2003046140A3 (en) 2003-07-31

Family

ID=23301428

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/037861 Ceased WO2003046140A2 (en) 2001-11-27 2002-11-26 Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample

Country Status (7)

Country Link
US (2) US20040023309A1 (https=)
EP (1) EP1461616A4 (https=)
JP (1) JP2005510696A (https=)
CN (1) CN100593721C (https=)
CA (1) CA2507024A1 (https=)
WO (1) WO2003046140A2 (https=)
ZA (1) ZA200405072B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011051076A1 (de) 2011-06-15 2012-12-20 Diagenics Se Verfahren zum Ermitteln des ischämischen Levels eines schlaganfallverdächtigen Patienten
CN104897631A (zh) * 2015-06-01 2015-09-09 上海凯创生物技术有限公司 糖原磷酸化酶同工酶bb近红外荧光法检测试剂盒
CN105628930A (zh) * 2015-12-22 2016-06-01 山东博科生物产业有限公司 一种灵敏度高的胶乳增强免疫比浊法肌钙蛋白i检测试剂

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
JP6325022B2 (ja) * 2006-04-04 2018-05-16 シングレックス，インコーポレイテッド トロポニンの分析のための高感度のシステムおよび方法
DE502007001254D1 (de) * 2007-06-29 2009-09-17 Brainlab Ag Bestimmung von Korrespondenz-Objekt-Paaren zur medizinischen Navigation
JP5609107B2 (ja) * 2009-12-28 2014-10-22 東ソー株式会社 トロポニンｉの免疫測定方法
WO2014121252A1 (en) * 2013-02-04 2014-08-07 The General Hospital Corporation Biomarkers for stroke diagnosis
EP3933384A1 (en) 2013-03-15 2022-01-05 Hycor Biomedical, LLC Device and associated method for performing luminescence and fluorescence measurements of a sample
ES2792227T3 (es) 2014-09-26 2020-11-10 Somalogic Inc Predicción de evento de riesgo cardiovascular y usos de la misma
CN104678105A (zh) * 2015-01-16 2015-06-03 镇江市第一人民医院 检测Cripto-1的酶联免疫试剂盒及其制备方法
CN106290883B (zh) * 2015-06-01 2018-06-29 上海凯创生物技术有限公司 糖原磷酸化酶同工酶bb胶体金法检测试剂盒
JP6785372B2 (ja) * 2016-09-30 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ
CN111693719A (zh) * 2019-03-11 2020-09-22 程明 一种肌红蛋白测定试剂盒及其测定方法
CN111693710A (zh) * 2019-03-12 2020-09-22 程明 一种肌钙蛋白i测定试剂盒及其制备方法
CN114152740A (zh) * 2021-11-16 2022-03-08 珠海科域生物工程股份有限公司 一种酶促化学发光试剂盒、制备方法及检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2027434C (en) * 1990-10-12 1999-01-05 George Jackowski Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof
US5795725A (en) * 1995-04-18 1998-08-18 Biosite Diagnostics Incorporated Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays
DE69633780T3 (de) * 1995-04-18 2011-05-05 Biosite Incorporated, San Diego Verfahren zum assay von troponin i und t und komplexen von troponin i und t und auswahl von antikörpern zur verwendung in immunoassays
US6429026B1 (en) * 1996-04-08 2002-08-06 Innotrac Diagnostics Oy One-step all-in-one dry reagent immunoassay
EP0949508A1 (en) * 1998-04-08 1999-10-13 Dako A/S Method, antigen complex and kit for diagnosing Lyme borreliosis
US6099469A (en) * 1998-06-02 2000-08-08 Armstrong; E. Glenn Reflex algorithm for early and cost effective diagnosis of myocardial infractions suitable for automated diagnostic platforms
US6214629B1 (en) * 1998-08-06 2001-04-10 Spectral Diagnostics, Inc. Analytical test device and method for use in medical diagnoses

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011051076A1 (de) 2011-06-15 2012-12-20 Diagenics Se Verfahren zum Ermitteln des ischämischen Levels eines schlaganfallverdächtigen Patienten
WO2012171878A1 (de) 2011-06-15 2012-12-20 Diagenics Se Verfahren zum ermitteln des ischämischen levels eines schlaganfallverdächtigen patienten
CN104897631A (zh) * 2015-06-01 2015-09-09 上海凯创生物技术有限公司 糖原磷酸化酶同工酶bb近红外荧光法检测试剂盒
CN105628930A (zh) * 2015-12-22 2016-06-01 山东博科生物产业有限公司 一种灵敏度高的胶乳增强免疫比浊法肌钙蛋白i检测试剂

Also Published As

Publication number Publication date
AU2002346529A1 (en) 2003-06-10
CN100593721C (zh) 2010-03-10
ZA200405072B (en) 2005-06-27
JP2005510696A (ja) 2005-04-21
CN1618017A (zh) 2005-05-18
WO2003046140A3 (en) 2003-07-31
EP1461616A2 (en) 2004-09-29
US20040023309A1 (en) 2004-02-05
US20070166776A1 (en) 2007-07-19
CA2507024A1 (en) 2003-06-05
EP1461616A4 (en) 2005-08-10

Similar Documents

Publication Publication Date Title
US20070166776A1 (en) Immunoassay and kit for an early and simultaneous detection of biochemical markers in a patient's sample
AU2016203292B2 (en) Monoclonal antibody, and immunoassay using same
JP2014515476A (ja) 非特異的結合を減少させるためのイムノアッセイ方法及び試薬
KR100249752B1 (ko) 항체의특정클래스에특이적인간섭억제시약
US20110312922A1 (en) EDTA Resistant S100A12 Complexes (ERAC)
US20040248216A1 (en) Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor
US5583003A (en) Agglutination assay
US8664007B2 (en) Immune complex-specific antibodies for increased sensitivity in immunoassay array tests
CN118515772A (zh) 抗生物素单克隆抗体及其制备方法和应用
AU2002346529B2 (en) Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample
CA2066736A1 (en) Agglutination assay
CN117616277A (zh) 甲状腺球蛋白的免疫检测及用于其的试剂盒
JPH0611507A (ja) ヒトポドカリキシンの測定方法
JPH0313864A (ja) ＴＮＦ―αの測定方法，キット及び診断方法
JPS6175262A (ja) 免疫複合体測定用試薬及びそれを用いた免疫複合体の測定法
JP2025107986A (ja) イムノアッセイにおける干渉を低減するための方法およびキット
AU633633B2 (en) Agglutination assay
JP2001153868A (ja) カゼインホスホペプチド（ｃｐｐ）の免疫学的測定法
JP4505800B2 (ja) 抗腎タイプｉｖモノクロ−ナル抗体
JPH1114626A (ja) Ｃａ１２５の測定方法
JP4037586B2 (ja) ヒトメダラシンの免疫学的測定方法
JPH04325095A (ja) 抗ヒトｉｌ−６モノクロ−ナル抗体及び該抗体を使用するｉｌ−６の測定方法
WO1983001118A1 (en) Monoclonal antibody detection system
JPH1082786A (ja) 免疫測定方法及びその測定試薬
JPH1082787A (ja) 免疫測定方法及びその測定試薬

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003547575

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 346/MUMNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002346529

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004/05072

Country of ref document: ZA

Ref document number: 200405072

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002784596

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028275675

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002784596

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2507024

Country of ref document: CA